| # | Country | Total Patents | |
|---|---|---|---|
| #1 | WIPO (World Intellectual Property Organization) | 6 | |
| #2 | EPO (European Patent Office) | 4 | |
| #3 | United States | 3 | |
| #4 | Canada | 2 | |
| #5 | China | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Measurement |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Peptides | |
| #3 | Medical preparations | |
| #4 | Analysing materials |
| # | Name | Total Patents |
|---|---|---|
| #1 | Monticello Daniel J | 14 |
| #2 | Pienkos Philip T | 14 |
| #3 | Bishop Jeffrey S | 4 |
| #4 | Loomis Katrina A | 3 |
| #5 | Loomis A Katrina | 2 |
| #6 | Pienkos Philip P | 1 |
| #7 | Coco Wayne M | 1 |
| Publication | Filing date | Title |
|---|---|---|
| WO2008076788A2 | Optimized pan-her ligands | |
| EP2043676A2 | Insulin-like growth factor-1 receptor antagonists | |
| WO2008005983A2 | Pan-her antagonists and methods of use | |
| EP2044246A2 | Dominant negative ligand drug discovery system | |
| US2006154333A1 | Pan-HER antagonists and methods of use | |
| CA2575278A1 | Epidermal growth factor receptor antagonists and methods of use | |
| US7084246B2 | Epidermal growth factor agonists |